Clinical Trials

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT07052916 2026-05-26

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

60 enrolled

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT04439292 2026-05-19

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

44 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT07292272 2026-05-18

HALTAging-1

Phase 2 Recruiting

180 enrolled

Hodgkin Disease, Leukemia, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT03413800 2026-05-08

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Phase 2 Completed

10 enrolled

Multiple Myeloma, Hematologic Neoplasms

NCT04439110 2026-05-08

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

38 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04634552 2026-05-08

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT04439266 2026-05-07

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

5 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439279 2026-05-07

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-05-07

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439344 2026-05-07

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

53 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05887167 2026-05-07

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Phase 1 Recruiting

20 enrolled

Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04439123 2026-05-06

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439175 2026-05-06

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

70 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04771572 2026-05-05

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase 1 Recruiting

100 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04439227 2026-05-04

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

35 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01231412 2026-04-30

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase 3 Completed

174 enrolled 12 charts

Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04439136 2026-04-29

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

40 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439253 2026-04-29

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05646576 2026-04-21

PEACE

90 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT07523555 2026-04-13

ADAPT-HEM

Phase 1/2 Recruiting

96 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04684108 2026-04-07

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Phase 1 Active not recruiting

61 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT05972577 2026-04-06

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Phase NA Completed

30 enrolled

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT01315132 2026-03-19

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

Phase 2 Completed

47 enrolled 8 charts

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05866757 2026-03-04

Discontinuation Study

70 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT07297160 2026-03-04

CALySSEY

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05745285 2026-02-20

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

LymphoidMyeloidOther hematologic neoplasmPlasma cell

400 enrolled

Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasmPlasma cell

204 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT06296368 2026-01-28

DISCOVERY

500 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03159702 2026-01-27

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

Phase 2 Completed

43 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Multiple Myeloma, Hematologic Neoplasms

NCT05063591 2026-01-15

BRUOG-407

Phase NA Completed

18 enrolled 8 charts

Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07071909 2026-01-06

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

Phase 1/2 Withdrawn

Infections, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT04364256 2026-01-02

Muscle Stimulation for Physical Function During Stem Cell Transplant

Phase NA Completed

46 enrolled

Lymphoma, Multiple Myeloma, Muscular Atrophy, Hematologic Neoplasms

NCT07270263 2025-12-26

HEM-DOAC

Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

100 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Pulmonary Embolism, Hematologic Neoplasms, Venous Thromboembolism

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

250 enrolled

Phase 1 Not yet recruiting

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT07255898 2025-12-01

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

33 enrolled

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Multiple Myeloma, Hematologic Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

12 enrolled

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06398457 2025-09-26

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Phase EARLY_PHASE1 Recruiting

8 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT06487247 2025-09-17

HEME Home Transfusion Program

LymphoidMyeloidOther hematologic neoplasmPlasma cell

700 enrolled

Hematologic Diseases, Leukemia, Lymphoma, Myelodysplastic Syndromes, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07107204 2025-09-17

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1/2 Not yet recruiting

116 enrolled